 |
|
New findings show Enbrel significantly reduced levels of C-reactive protein
February 04, 2008Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein (CRP), a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment. Median reduction in CRP levels was 10 times greater in the ENBREL treated group compared to the placebo treated group. These results will be presented today at the American Academy of Dermatology Scientific Meeting in San Antonio, Texas.
Psoriasis is a non-contagious, chronic disease in which the immune system causes skin cells to grow at an accelerated rate. Approximately 80 percent of psoriasis patients have plaque psoriasis, which is characterized by painful and itchy, red, scaly patches.
Key findings of the analysis of moderate to severe plaque psoriasis patients without psoriatic arthritis (n=501) demonstrated:
* Patients had intermediate to high baseline CRP levels, indicating that psoriasis is a systemic inflammatory disease.
* The median reduction in CRP levels from baseline was 1.0 mg/L in psoriasis patients receiving ENBREL vs. 0.1 mg/L in those receiving placebo (P<0.001).
"The finding that patients with moderate to severe plaque psoriasis had increased inflammation, as exhibited by elevated CRP levels, reinforces that psoriasis is not only a skin disease, but in some patients may be a serious medical condition," said Bruce Strober, M.D., Ph.D., study investigator, co-director of the Psoriasis and Psoriatic Arthritis Center of New York University Medical Center. "The results from this study are encouraging because they show that ENBREL not only improved the symptoms of patients with moderate to severe psoriasis, but reduced their levels of CRP as well. However, further research is needed to better understand whether reducing CRP levels lowers the risk for developing conditions such as cardiovascular disease that may derive from increased systemic inflammation."
The analysis also evaluated the relationship between CRP levels and body mass index (BMI), an indicator of body fat, in people with psoriasis without psoriatic arthritis. Notably, obesity is common among patients with psoriasis. Findings showed:
* Heavier patients with higher BMIs tended to have higher CRP levels.
* ENBREL decreased CRP levels in overweight and obese psoriasis patients. Specifically, among patients treated with ENBREL, median CRP values decreased from high or intermediate levels to intermediate or low levels after 12 weeks of treatment in all BMI groups except normal weight psoriasis patients.
The 24-week registrational study was originally designed to test the efficacy and safety of ENBREL therapy in patients with moderate to severe plaque psoriasis, the results of which have previously been reported in The New England Journal of Medicine. The primary objective of this retrospective analysis was to evaluate the effectiveness of ENBREL in reducing levels of CRP in psoriasis patients with and without psoriatic arthritis from baseline to week 12 compared to placebo. Secondary objectives were to assess CRP values at baseline, and to assess the relationship between CRP levels and patient characteristics, such as BMI, use of statin drugs, and Psoriasis Area and Severity Index (PASI). During the double-blind portion of the analysis, patients were randomly assigned to receive either placebo or ENBREL injections (25 mg once weekly, 25 mg twice weekly or 50 mg twice weekly) for 12 weeks. During the subsequent 12 weeks, patients who initially received ENBREL continued to receive treatment with ENBREL at the same dose, while patients in the placebo group switched to ENBREL 25 mg twice weekly.
ABOUT C-REACTIVE PROTEIN
CRP is a blood protein that is a marker for a number of inflammatory conditions and is an indicator of risk for cardiovascular disease. The development of a high sensitivity CRP assay (hs-CRP) has enabled detection of low levels of CRP previously undetectable by traditional CRP evaluations. Even low levels of CRP (i.e., less than 3 mg/L), as measured by this high sensitivity test, are associated with increased cardiovascular risk; however it is not clear that CRP plays a causal role in the development of cardiovascular disease. The safety and efficacy of ENBREL have not been established for decreasing cardiovascular risk.
ABOUT ENBREL
ENBREL is a fully human soluble tumor necrosis factor (TNF) receptor. ENBREL was first approved in 1998 for moderate to severe rheumatoid arthritis and has since been used in nearly 500,000 patients worldwide across indications.
ENBREL indications in the U.S.:
* ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderate to severe rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.
* ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease modifying antirheumatic drugs.
* ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.
* ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
* ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
What important information do I need to know about taking prescription Enbrel® (etanercept)"
ENBREL is a type of protein called a tumor necrosis factor (TNF) blocker that blocks the action of a substance your body's immune system makes called TNF. People with an immune disease, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis, have too much TNF in their bodies. ENBREL can reduce the amount of TNF in the body to normal levels, helping to treat your disease. But, in doing so, ENBREL can also lower the ability of your immune system to fight infections.
All medicines have side effects, including ENBREL. Possible side effects of ENBREL include:
* Serious infections
o Many occurred in people prone to infection, such as those with advanced or poorly controlled diabetes
o Some serious infections have been fatal
o Rare cases of tuberculosis have occurred
* What not to do
o Do not start ENBREL if you have an infection, such as an open sore or the flu, or are allergic to ENBREL or its components
* What to do
o Tell your doctor if you are prone to infection or have had hepatitis B
o Stop ENBREL if a serious infection occurs
o Contact your doctor if you have questions about ENBREL or develop an infection
o Tell your doctor if you have ever been treated for heart failure
o Serious nervous system disorders, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes
o Tell your doctor if you have ever had any of these disorders or if you develop them after starting ENBREL
* Rare reports of serious blood disorders (some fatal)
o Contact your doctor immediately if you develop symptoms, such as persistent fever, bruising, bleeding, or paleness
* In medical studies of all TNF blockers, including ENBREL, a higher rate of lymphoma (a type of cancer) was seen compared to the general population. The risk of lymphoma may be up to several-fold higher in rheumatoid arthritis and psoriasis patients
* The role of TNF blockers, including ENBREL, in the development of lymphoma is unknown
* ENBREL can cause injection site reaction
* In a medical study of patients with JRA, infection, headache, abdominal pain, vomiting, and nausea occurred more frequently than in adults
o The kinds of infections reported were generally mild and similar to those usually seen in children
o Other serious adverse reactions were reported rarely, including serious infection (2 percent) and depression/personality disorder (1 percent)
Porter Novelli
* Patients had intermediate to high baseline CRP levels, indicating that psoriasis is a systemic inflammatory disease.
* The median reduction in CRP levels from baseline was 1.0 mg/L in psoriasis patients receiving ENBREL vs. 0.1 mg/L in those receiving placebo (P<0.001).
"The finding that patients with moderate to severe plaque psoriasis had increased inflammation, as exhibited by elevated CRP levels, reinforces that psoriasis is not only a skin disease, but in some patients may be a serious medical condition," said Bruce Strober, M.D., Ph.D., study investigator, co-director of the Psoriasis and Psoriatic Arthritis Center of New York University Medical Center. "The results from this study are encouraging because they show that ENBREL not only improved the symptoms of patients with moderate to severe psoriasis, but reduced their levels of CRP as well. However, further research is needed to better understand whether reducing CRP levels lowers the risk for developing conditions such as cardiovascular disease that may derive from increased systemic inflammation."
The analysis also evaluated the relationship between CRP levels and body mass index (BMI), an indicator of body fat, in people with psoriasis without psoriatic arthritis. Notably, obesity is common among patients with psoriasis. Findings showed:
* Heavier patients with higher BMIs tended to have higher CRP levels.
* ENBREL decreased CRP levels in overweight and obese psoriasis patients. Specifically, among patients treated with ENBREL, median CRP values decreased from high or intermediate levels to intermediate or low levels after 12 weeks of treatment in all BMI groups except normal weight psoriasis patients.
The 24-week registrational study was originally designed to test the efficacy and safety of ENBREL therapy in patients with moderate to severe plaque psoriasis, the results of which have previously been reported in The New England Journal of Medicine. The primary objective of this retrospective analysis was to evaluate the effectiveness of ENBREL in reducing levels of CRP in psoriasis patients with and without psoriatic arthritis from baseline to week 12 compared to placebo. Secondary objectives were to assess CRP values at baseline, and to assess the relationship between CRP levels and patient characteristics, such as BMI, use of statin drugs, and Psoriasis Area and Severity Index (PASI). During the double-blind portion of the analysis, patients were randomly assigned to receive either placebo or ENBREL injections (25 mg once weekly, 25 mg twice weekly or 50 mg twice weekly) for 12 weeks. During the subsequent 12 weeks, patients who initially received ENBREL continued to receive treatment with ENBREL at the same dose, while patients in the placebo group switched to ENBREL 25 mg twice weekly.
ABOUT C-REACTIVE PROTEIN
CRP is a blood protein that is a marker for a number of inflammatory conditions and is an indicator of risk for cardiovascular disease. The development of a high sensitivity CRP assay (hs-CRP) has enabled detection of low levels of CRP previously undetectable by traditional CRP evaluations. Even low levels of CRP (i.e., less than 3 mg/L), as measured by this high sensitivity test, are associated with increased cardiovascular risk; however it is not clear that CRP plays a causal role in the development of cardiovascular disease. The safety and efficacy of ENBREL have not been established for decreasing cardiovascular risk.
ABOUT ENBREL
ENBREL is a fully human soluble tumor necrosis factor (TNF) receptor. ENBREL was first approved in 1998 for moderate to severe rheumatoid arthritis and has since been used in nearly 500,000 patients worldwide across indications.
ENBREL indications in the U.S.:
* ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderate to severe rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.
* ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease modifying antirheumatic drugs.
* ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.
* ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
* ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
What important information do I need to know about taking prescription Enbrel® (etanercept)"
ENBREL is a type of protein called a tumor necrosis factor (TNF) blocker that blocks the action of a substance your body's immune system makes called TNF. People with an immune disease, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis, have too much TNF in their bodies. ENBREL can reduce the amount of TNF in the body to normal levels, helping to treat your disease. But, in doing so, ENBREL can also lower the ability of your immune system to fight infections.
All medicines have side effects, including ENBREL. Possible side effects of ENBREL include:
* Serious infections
o Many occurred in people prone to infection, such as those with advanced or poorly controlled diabetes
o Some serious infections have been fatal
o Rare cases of tuberculosis have occurred
* What not to do
o Do not start ENBREL if you have an infection, such as an open sore or the flu, or are allergic to ENBREL or its components
* What to do
o Tell your doctor if you are prone to infection or have had hepatitis B
o Stop ENBREL if a serious infection occurs
o Contact your doctor if you have questions about ENBREL or develop an infection
o Tell your doctor if you have ever been treated for heart failure
o Serious nervous system disorders, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes
o Tell your doctor if you have ever had any of these disorders or if you develop them after starting ENBREL
* Rare reports of serious blood disorders (some fatal)
o Contact your doctor immediately if you develop symptoms, such as persistent fever, bruising, bleeding, or paleness
* In medical studies of all TNF blockers, including ENBREL, a higher rate of lymphoma (a type of cancer) was seen compared to the general population. The risk of lymphoma may be up to several-fold higher in rheumatoid arthritis and psoriasis patients
* The role of TNF blockers, including ENBREL, in the development of lymphoma is unknown
* ENBREL can cause injection site reaction
* In a medical study of patients with JRA, infection, headache, abdominal pain, vomiting, and nausea occurred more frequently than in adults
o The kinds of infections reported were generally mild and similar to those usually seen in children
o Other serious adverse reactions were reported rarely, including serious infection (2 percent) and depression/personality disorder (1 percent)
Porter Novelli
Psoriasis Current Events and Psoriasis News RSSCurry-cure? Spicing up the effectiveness of a potential disease-fighter
Scientists are reporting development of a nano-size capsule that boosts the body's uptake of curcumin, an ingredient in yellow curry now being evaluated in clinical trials for treatment of several diseases.
Skin-disease patients show brain immunity to faces of disgust
People with psoriasis - an often distressing dermatological condition that causes lesions and red scaly patches on the skin - are less likely to react to looks of disgust by others than people without the condition, new research has found.
Gene variation is 'major genetic determinant of psoriasis'
A specific genetic region that has been increasingly identified as the strongest genetic link to psoriasis has an even more significant role in the chronic skin disease than has been suspected, University of Utah medical researchers show in a new study.
Drug rescues memory lost to Alzheimer's disease
A drug similar to one used in clinical trials for treatment of rheumatoid arthritis and psoriasis has been found to rescue memory in mice exhibiting Alzheimer's symptoms.
Post-transplant combo can replace toxic immune-suppressing drugs in monkeys
Transplant patients rely on drugs to prevent graft rejection, but at the cost of serious side effects.
Psoriasis associated with cardiovascular disease and increased mortality
The skin disease psoriasis is associated with atherosclerosis (a buildup of plaque in the arteries) characterized by an increased prevalence of ischemic heart disease, cerebrovascular disease, peripheral artery disease and an increased risk of death.
Scientists discover new genetic immune disorder in children
Your immune system plays an important function in your health-it protects you against viruses, bacteria, and other toxins that can cause disease.
Study finds unexpected bacterial diversity on human skin
The health of our skin - one of the body's first lines of defense against illness and injury - depends upon the delicate balance between our own cells and the millions of bacteria and other one-celled microbes that live on its surface.
Vitamin D may halt lung function decline in asthma and COPD
Vitamin D may slow the progressive decline in the ability to breathe that can occur in people with asthma as a result of human airway smooth muscle (HASM) proliferation, according to researchers at the University of Pennsylvania.
Home UVB therapy for psoriasis as effective and safe as hospital treatment
For patients with psoriasis, treatment with ultraviolet B (UVB) at home is as effective and as safe as conventional hospital based phototherapy, concludes a study published on bmj.com today.
More Psoriasis Current Events and Psoriasis News Articles
 |
Healing Psoriasis: The Natural Alternative by John Pagano (Author) A leading researcher shares natural remedies for psoriasis According to the National Psoriasis Foundation, at least seven million people in the U.S. and more than 100 million worldwide suffer from this chronic skin disease. This book outlines Dr. Pagano's natural, drug-free treatment regimen that can alleviate, control, and even heal psoriasis without steroid creams, tar baths, injections, or ultraviolet treatments. Healing Psoriasis outlines a healthy diet and lifestyle and includes case histories, photos, recipes, and a chapter on eczema. John O. A. Pagano, DC (Englewood Cliffs, NJ), is a chiropractic physician who has conducted psoriasis research for more than 40 years. He has been a featured guest on CNBC, ABC, and Health Talk with Dr. Ronald Hoffman, and... |
 |
Loma Lux Homeopathic Medicine, Psoriasis, 8 fl oz (237 ml) by Loma Lux For relief from the scaling, itching and redness of Psoriasis and Seborrhea. Take orally. 2% Alcohol. Dermatologist Steven A. Smith, MD, developed the Loma Lux Psoriasis formula & has proven its effectiveness in treating thousands of patients for psoriasis and seborrheic dermatitis. Get relief from scaling, flaking, redness, pain and itching with Loma Lux Psoriasis. I spent hundreds of dollars on creams from the doctor; nothing worked. A miracle came in Loma Lux Psoriasis! before the first month was up I noticed a big difference in my psoriasis. My skin cleared with continued use. Loma Lux is dedicated to promote worldwide health and wholeness using natural, low dose, low side effect treatments, bringing freedom from chronic diseases. |
 |
Psoriasis Healing from the Inside Out by Heather J. Ferris (Author) "At last a beautifully written book on how to manage this difficult external condition by internal means. I will recommend this book to all my patients with psoriasis." Dr Stephen Falkner MB., Ch.B. Psoriasis Healing from the Inside Out is an important book for people with psoriasis and other conditions, who feel controlled by their diseases. The author Heather Ferris shares her own profound (and simple) experiences with healing addressing issues of body, mind and spirit. She provides practical techniques and opportunities to reflect on individual situations. The author's warm and caring style is evident as she invites us to experience a more peaceful inner environment. Reading this book reminds us to live full, healthy lives. |
 |
Your Healing Diet: A Quick Guide to Reversing Psoriasis and Chronic Diseases with Healing Foods by Deirdre Earls RD LD (Author) 'Your Healing Diet: A Quick Guide to Reversing Psoriasis and Chronic Diseases with Healing Foods' is a handbook written by Deirdre Earls, RD, LD, to make it faster and easier to eat in a way that enables the body to heal itself. A short guidebook which was designed to be very user-friendly, it also explains how food can create and reverse disease. In essense, the book distills common threads of success amongst several healing diets like Macrobiotics, Raw Foods, Alkalizing, Cancer and Heart Disease Prevention, Anti-Aging and Anti-inflammatory Diets. Then it demonstrates how you can easily incorporate healing habits into your busy lifestyle. Special segments discuss healing principles and what to expect when healing naturally. Whether or not you're an Austinite, you'll also find... |
 |
Adovia Natural Dead Sea Mud Soap - Great for Eczema, Psoriasis or Acne! by Adovia Mineral Skin Care Our All Natural Black Mud Soap contains a unique combination of Dead Sea minerals derived from Dead Sea Mud. This effective mud soap removes dirt and cleanses your skin, while simultaneously infusing it with minerals essential to keeping your skin hydrated and moisturized. Our Dead Sea mud soap is enriched with century old Dead Sea mud, leaving your skin cleansed and nourished. As more people are learning about the healing and beauty effects of black mud from The Dead Sea, this soap is becoming a very popular choice for skin care conscious people. |
 |
The Psoriasis Cure: A Drug-Free Guide to Stopping & Reversing the Symptoms of Psoriasis by Lisa LeVan (Author) This book offers hope for those who suffer from this debilitating systemic disease. Beyond causing scaly red patches on the skin, psoriasis can result in aching joints, listlessness, and arthritis. Featuring a nutritional approach to treatment, this book teaches the patient to eliminate allergic reactions and to add specific supplements to the diet. |
 |
Psoriasis: Everything You Need to Know (Your Personal Health) by Dr Richard G.B. Langley (Author) Helpful advice for relief of a chronic condition that affects millions. Psoriasis is a chronic inflammatory, non-contagious skin disease. Characterized by itchy, thick and raised red areas of skin covered with silvery-white scales, psoriasis affects 1 in 50 adults. This affliction makes it one of the world's most common skin disorders. Appearing at any age, it can affect relationships, the ability to work and to enjoy leisure activities. Psoriasis is a straightforward book about an all too common problem. The information is presented in clear, understandable terms for non-medical readers, covering: - Causes - Psychosocial effects - Diagnosis - Treatment options - Psoriatic arthritis - Psoriasis in children. Psoriasis includes line drawings, case studies, a... |
 |
Oxipor VHC Psoriasis Lotion, Coal Tar Solution, 4-Ounce Bottle by Oxipor Oxipor psoriasis lotion controls itching, and relieves redness and scaling. |
 |
Psoriasis: The Real Way Out: A Self-Education Guide to Complete Natural Healing by Jerry G. Scott R.N.C. (Author) This is a book for the determined, not for the quick fix crowd. A clear understanding of the underlying causes of psoriasis is presented, one that flies in the face of current drug-oriented treatments, nevertheless one that recognizes the causes and alleviation of psoriasis that have been known for decades. Leading edge strategies are also revealed, and resources are listed. The book is blunt, and does not coddle the reader. Rather, it requires participation if the reader is to be healed of the condition, and very specific solutions are offered in a comprehensive plan of action. Uniquely, the author offers his personal help when readers are registered through links that are provided in the book. |
 |
Mg 217 Intensive Strength Medicated Tar Ointment for Psoriasis - 3.8 Oz by Mg 217 Mg 217 Intensive Strength Medicated Tar Ointment for Psoriasis is specially formulated to control the itching, redness and scaling from skin psoriasis. |
| © 2009 BrightSurf.com |